Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
Demand normalisation post the second wave contributed to the steady growth
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Subscribe To Our Newsletter & Stay Updated